These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29296866)

  • 1. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.
    Thordardottir M; Lindqvist EK; Lund SH; Costello R; Burton D; Korde N; Mailankody S; Eiriksdottir G; Launer LJ; Gudnason V; Harris TB; Landgren O; Kristinsson SY
    Blood Adv; 2017 Nov; 1(24):2186-2192. PubMed ID: 29296866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
    Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.
    Chang SH; Luo S; Thomas TS; O'Brian KK; Colditz GA; Carlsson NP; Carson KR
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
    Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
    Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
    Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance.
    Georgakopoulou R; Andrikopoulou A; Sergentanis TN; Fiste O; Zagouri F; Gavriatopoulou M; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):361-367. PubMed ID: 33582053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
    Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
    JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
    Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Cerhan JR; Rajkumar SV
    N Engl J Med; 2018 Jan; 378(3):241-249. PubMed ID: 29342381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
    Landgren O; Hofmann JN; McShane CM; Santo L; Hultcrantz M; Korde N; Mailankody S; Kazandjian D; Murata K; Thoren K; Ramanathan L; Dogan A; Rustad E; Lu SX; Akhlaghi T; Kristinsson SY; Björkholm M; Devlin S; Purdue MP; Pfeiffer RM; Turesson I
    JAMA Oncol; 2019 Sep; 5(9):1293-1301. PubMed ID: 31318385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.
    Thorsteinsdottir S; Lund SH; Lindqvist EK; Thordardottir M; Sigurdsson G; Costello R; Burton D; Steingrimsdottir H; Gudnason V; Eiriksdottir G; Siggeirsdottir K; Harris TB; Landgren O; Kristinsson SY
    Blood Adv; 2017 Dec; 1(27):2790-2798. PubMed ID: 29296931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association of Agent Orange (AO) Exposure with Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Progression: A Population-based Study of Vietnam War Era Veterans.
    Liu LW; Wang M; Grandhi N; Schroeder MA; Thomas T; Vargo K; Gao F; Sanfilippo KM; Chang SH
    Res Sq; 2023 Oct; ():. PubMed ID: 37886452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Socioeconomic Position is Positively Associated with Monoclonal Gammopathy of Undetermined Significance in a Population-based Cohort Study.
    Schmidt B; Debold E; Frank M; Arendt M; Dragano N; Dürig J; Dührsen U; Moebus S; Erbel R; Jöckel KH; Eisele L
    Ann Hematol; 2019 Dec; 98(12):2761-2767. PubMed ID: 31691002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
    Go RS; Gundrum JD; Neuner JM
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
    Stelmach-Gołdyś A; Czarkowska-Paczek B
    Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.
    Baldursdóttir TR; Löve ÞJ; Gíslason GK; Björkholm M; Mellqvist UH; Lund SH; Blimark CH; Turesson I; Hultcrantz M; Landgren O; Kristinsson SY
    Eur J Haematol; 2021 Mar; 106(3):380-388. PubMed ID: 33295006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.